Physician profile
Robert L Thomas
NPI 1841353083
$3,716.13
in general payments reported to CMS, 2019-2025
22 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $425 · 2021: $812 · 2022: $862 · 2023: $251 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $917.38 | 2019-2025 | Xarelto, Spravato |
| Abbvie INC. | $474.78 | 2019-2025 | |
| Allergan, INC. | $390.72 | 2019-2020 | |
| Amgen INC. | $290.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $210.79 | 2021-2022 | |
| Lilly USA, LLC | $206.09 | 2019-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $201.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $180.63 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $152.40 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $137.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.72 | 2021-2022 | |
| Pfizer INC. | $94.58 | 2020 | |
| Amarin Pharma, INC. | $76.16 | 2019-2022 | |
| Novo Nordisk INC | $75.59 | 2019-2023 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $37.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.98 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $23.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $19.55 | 2019 | |
| Esperion Therapeutics, INC. | $18.22 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.09 | 2019 | |
| Radius Health, INC. | $17.95 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.